Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CMPX

CMPX - Compass Therapeutics Inc Stock Price, Fair Value and News

1.10USD-0.01 (-0.90%)Delayed

Market Summary

CMPX
USD1.10-0.01
Delayed
-0.90%

CMPX Stock Price

View Fullscreen

CMPX RSI Chart

CMPX Valuation

Market Cap

151.3M

Price/Earnings (Trailing)

-3.33

EV/EBITDA

-2.85

Price/Free Cashflow

-3.58

MarketCap/EBT

-3.33

CMPX Price/Earnings (Trailing)

CMPX Profitability

Return on Equity

-28.93%

Return on Assets

-28.2%

Free Cashflow Yield

-27.95%

CMPX Fundamentals

CMPX Earnings

Earnings (TTM)

-45.4M

Earnings Growth (Yr)

-37.64%

Earnings Growth (Qtr)

19.59%

Breaking Down CMPX Revenue

Last 7 days

-0.9%

Last 30 days

-29.5%

Last 90 days

-48.4%

Trailing 12 Months

-66.5%

How does CMPX drawdown profile look like?

CMPX Financial Health

Current Ratio

40.74

CMPX Investor Care

Shares Dilution (1Y)

8.76%

Tracking the Latest Insider Buys and Sells of Compass Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 08, 2024
bisker-leib vered
sold (taxes)
-71,337
1.45
-49,198
chief executive officer
Feb 08, 2024
schuetz thomas j.
sold (taxes)
-64,933
1.45
-44,782
president
Jan 09, 2024
bisker-leib vered
acquired
3,383,530
1.93
1,753,120
chief executive officer
Jan 09, 2024
schuetz thomas j.
acquired
1,230,380
1.93
637,500
president of r&d
Nov 17, 2023
schuetz thomas j.
sold (taxes)
-66,037
1.5
-44,025
chief executive officer
Nov 17, 2023
bisker-leib vered
sold (taxes)
-96,622
1.5
-64,415
chief operating officer
Mar 10, 2023
schuetz thomas j.
bought
33,700
3.37
10,000
chief executive officer
Feb 27, 2023
schuetz thomas j.
bought
79,600
3.98
20,000
chief executive officer
Feb 15, 2023
schuetz thomas j.
bought
77,200
3.86
20,000
chief executive officer
Feb 08, 2023
bisker-leib vered
acquired
-
-
400,000
chief operating officer

1–10 of 50

Which funds bought or sold CMPX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 29, 2024
Opaleye Management Inc.
new
-
6,276,600
6,276,600
1.37%
May 20, 2024
Virtu Financial LLC
sold off
-100
-44,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-75.12
-88,681
40,932
-%
May 16, 2024
B. Riley Wealth Advisors, Inc.
unchanged
-
20,500
98,500
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.91
-5,265
18,168
-%
May 15, 2024
Blue Owl Capital Holdings LP
unchanged
-
1,188,480
5,602,830
1.12%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-60.78
-387,125
383,659
-%
May 15, 2024
ALGERT GLOBAL LLC
new
-
33,000
33,000
-%
May 15, 2024
CAXTON CORP
unchanged
-
18,256
86,062
0.49%
May 15, 2024
DAFNA Capital Management LLC
unchanged
-
49,090
231,426
0.05%

1–10 of 50

Are Funds Buying or Selling CMPX?

Are funds buying CMPX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CMPX
No. of Funds

Unveiling Compass Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 22, 2024
orbimed advisors llc
13.7%
18,791,422
SC 13D/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
7.75%
9,880,000
SC 13G/A
Feb 01, 2024
janus henderson group plc
6.0%
7,647,740
SC 13G
Nov 27, 2023
adage capital partners gp, l.l.c.
5.66%
7,211,800
SC 13G
Feb 14, 2023
rock springs capital management lp
4.22%
5,333,188
SC 13G/A
Feb 13, 2023
foresite capital fund v, l.p.
3.5%
0
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Nov 14, 2022
commander aggregator, lp
6.17%
0
SC 13D
Nov 10, 2022
orbimed advisors llc
14.9%
18,791,422
SC 13D/A

Recent SEC filings of Compass Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 17, 2024
8-K
Current Report
May 29, 2024
DEFA14A
DEFA14A
May 28, 2024
8-K
Current Report
May 13, 2024
8-K
Current Report
May 13, 2024
10-Q
Quarterly Report
Apr 29, 2024
DEFA14A
DEFA14A
Apr 29, 2024
DEF 14A
DEF 14A
Apr 29, 2024
ARS
ARS
Apr 25, 2024
8-K
Current Report
Mar 22, 2024
SC 13D/A
13D - Major Acquisition

Peers (Alternatives to Compass Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Compass Therapeutics Inc News

Latest updates
Defense World20 Jun 202407:16 am
InvestorPlace13 May 202407:00 am

Compass Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q22019Q12018Q4
Assets2.7%16115717017918820012814014715435.0041.0048.0052.0061.0070.0050.0030.0042.0053.0065.00
  Current Assets3.1%15915416717518419512313514014729.0035.0042.0050.0058.0067.000.0026.000.000.0059.00
    Cash Equivalents-2.3%24.0024.0030.0019.0027.0035.0016.0026.0013614526.0031.0040.0047.0056.0065.000.0025.0038.000.0058.00
  Net PPE-17.1%1.001.001.001.001.002.002.002.002.002.001.001.001.001.002.003.00-4.00--5.00
Liabilities-51.0%4.008.0010.0011.0013.0018.0012.0013.0012.0014.0011.0012.0015.0012.0013.0017.0018.0019.0019.0019.0020.00
  Current Liabilities-50.1%4.008.009.0010.0011.0016.0010.0011.009.0011.008.008.0011.0010.0010.0012.000.0010.000.000.008.00
  Long Term Debt--------------2.004.006.00-9.00--11.00
    LT Debt, Current-----------4.006.007.007.007.007.00-6.00--4.00
    LT Debt, Non Current--------------2.004.006.00-9.00--11.00
Shareholder's Equity5.7%15714916016817518211612713414024.0029.0033.0040.0047.0053.00-11.00---
  Retained Earnings-3.4%-326-315-301-291-280-272-261-249-240-233-220-214-158-151-143-133-0.11-121-0.08-0.07-87.16
  Additional Paid-In Capital4.2%483464462461456455378377375374244244192191190187-3.00---
Shares Outstanding7.8%13812812712712612610110110110155.0052.00---------
Float----283---184---180---------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-12.4%-13,888-12,354-5,922-10,113-12,229-10,641-10,942-4,600-7,942-4,665-3,457-5,939-5,605-6,573-7,169-5,300-7,761-2,799-6,704--9.81
  Share Based Compensation25.2%2,0031,6001,6251,6281,2671,0251,2871,4441,5741,1869879089481,0502,536183247226249--
Cashflow From Investing-164.9%-4,0996,31417,049-6674,269-46,6461,180-105,541-193-776-367-614-13.006.00-7.0051.00-12.00-185-27.00--
Cashflow From Financing11133.5%17,433-15821.003,03141.0075,7525.00--124,236-1,875-1,875-1,875-1,875-2,677-10.008.00--10.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CMPX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating Expense [Member]  
Research and development$ 9,522$ 6,638
General and administrative3,2483,073
Total operating expenses12,7709,711
Loss from operations(12,770)(9,711)
Other income1,9831,874
Loss before income tax expense(10,787)(7,837)
Income tax expense00
Net loss$ (10,787)$ (7,837)
Net loss per share - basic and diluted (in dollars per share)$ (0.08)$ (0.06)
Basic and diluted weighted average shares outstanding (in shares)136,608126,375
Other comprehensive loss:  
Net loss$ (10,787)$ (7,837)
Unrealized (loss) gain on marketable securities(127)156
Comprehensive loss$ (10,914)$ (7,681)

CMPX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 23,674$ 24,228
Marketable securities132,581128,233
Prepaid expenses and other current assets2,3561,420
Total current assets158,611153,881
Property and equipment, net744898
Operating lease, right-of-use ("ROU") asset1,4671,776
Other assets320320
Total assets161,142156,875
Current liabilities:  
Accounts payable8544,090
Accrued expenses1,8152,514
Operating lease obligations, current portion1,2241,197
Total current liabilities3,8937,801
Operating lease obligations, long-term portion189536
Total liabilities4,0828,337
Commitments and Contingencies 
Stockholders' equity:  
Common stock, $0.0001 par value: 300,000 shares authorized; 137,589 and 127,668 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively1413
Additional paid-in-capital483,231463,796
Accumulated other comprehensive (loss) income(90)37
Accumulated deficit(326,095)(315,308)
Total stockholders' equity157,060148,538
Total liabilities and stockholders' equity$ 161,142$ 156,875
CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEcompasstherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES26

Compass Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Compass Therapeutics Inc? What does CMPX stand for in stocks?

CMPX is the stock ticker symbol of Compass Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Compass Therapeutics Inc (CMPX)?

As of Fri Jun 21 2024, market cap of Compass Therapeutics Inc is 151.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CMPX stock?

You can check CMPX's fair value in chart for subscribers.

What is the fair value of CMPX stock?

You can check CMPX's fair value in chart for subscribers. The fair value of Compass Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Compass Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CMPX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Compass Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CMPX is over valued or under valued. Whether Compass Therapeutics Inc is cheap or expensive depends on the assumptions which impact Compass Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CMPX.